Evidence map›Paper›PMID 36625289›Full record

ArticleThe Kaohsiung journal of medical sciences2023

Clinical prognosis of surgical resection versus transarterial chemoembolization for single large hepatocellular carcinoma (≥5 cm): A propensity score matching analysis.

Pei-Min Hsieh, Pojen Hsiao, Yaw-Sen Chen, Jen-Hao Yeh, Chao-Ming Hung, Hung-Yu Lin, Ching-Hou Ma, TaoQian Tang, Yu Wei Huang, Pin-Nan Cheng and 4 more

Open access · goldAbstract read
In one paragraph

Article in The Kaohsiung journal of medical sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Pei-Min HsiehDepartment of Surgery, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
Pojen HsiaoDivision of Gastroenterology and Hepatology, Department of Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
Yaw-Sen ChenDepartment of Surgery, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
Jen-Hao YehDivision of Gastroenterology and Hepatology, Department of Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
Chao-Ming HungDepartment of Surgery, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
Hung-Yu LinDepartment of Surgery, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
Ching-Hou MaDepartment of Orthopedic Surgery, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
TaoQian TangDivision of Gastroenterology and Hepatology, Department of Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
Yu Wei HuangSchool of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan.
Pin-Nan ChengDivision of Gastroenterology and Hepatology, Department of Internal Medicine, College of Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.
Kun-Chou HsiehDepartment of Surgery, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
Kuang-Chun HuHealthy Evaluation Center and Division of Gastroenterology, Department of Internal Medicine, MacKay Memorial Hospital, Taipei, Taiwan.
Ming-Jong BairMackay Medical College, New Taipei, Taiwan.
Chih-Wen LinDivision of Gastroenterology and Hepatology, Department of Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.ORCID https://orcid.org/0000-0003-2344-5056
E-Da Hospital · TWMackay Memorial Hospital · TWChina Medical University · TWNational Cheng Kung University Hospital · TW

Funding

E-Da Hospital and EDPJ111075E-Da Hospital EDAHP104047E-Da Hospital EDAHP106054E-Da Hospital EDAHP107041E-Da Hospital EDAHP108036E-Da Hospital EDAHP108037E-Da Hospital EDAHP108038E-Da Hospital EDAHP109044E-Da Hospital EDAHP109057E-Da Hospital EDAHP110035E-Da Hospital EDAHP110036E-Da Hospital EDAHP110037E-Da Hospital EDAHP110040E-Da Hospital EDAHP111004E-Da Hospital EDAHP111008E-Da Hospital EDAHP111013E-Da Hospital EDAHP111025E-Da Hospital EDAHS111040E-Da Hospital EDCHP105003E-Da Hospital EDDHM109001E-Da Hospital EDPJ103040E-Da Hospital EDPJ104019E-Da Hospital EDPJ109025E-Da Hospital EDPJ109072E-Da Hospital EDPN110061Liver Disease Prevention and Treatment Research FoundationNational Cheng Kung University NCKUEDA10803, NCKUEDA10916National Health Research Institutes NHRI-109BCCO-MF202016-03National Science and Technology Council 110-2314-B-214-004-MY1, 111-2314-B-214-008-MY1
6 · The paper itself

Abstract

Favorable prognostic factors and therapeutic strategies are important for patients with single large hepatocellular carcinoma (HCC). This retrospective study aimed to investigate the prognostic factors in patients with single large (≥5 cm) HCC with Child-Pugh (CP) class A patients and to recommend therapeutic strategies. Overall, 298 HCC patients with single and large (≥5 cm) tumors with CP class A, but without distant metastasis and macrovascular invasion were included, and their clinicopathological data, overall survival (OS), and progression-free survival (PFS) were recorded. OS and PFS was analyzed by the Kaplan-Meier method and Cox regression analysis. Propensity score matching (PSM) analysis was performed. The 298 HCC patients were 79.2% male and median age of 64 years. For the initial treatment, surgical resection (SR) and transarterial chemoembolization (TACE) was 50.8% and 49.2%, respectively. The OS and PFS were significantly higher in patients receiving SR than those receiving TACE before and after PSM. Furthermore, in multivariate analysis, cirrhosis (Hazard ratio [HR]: 2.04; 95% confidence interval [CI]: 1.35-3.03, p < 0.001, CP class A5/6 [HR: 4.01; 95% CI: 2.43-6.66, p < 0.001], and initial treatment [SR vs. TACE HR = 3.23; 95% CI: 2.13-5.01, p < 0.001]) remained significantly associated with mortality. Moreover, in multivariate analysis, CP class A5/6 (HR: 3.23; 95% CI: 1.89-5.88, p < 0.001), and initial treatment (Resection vs. TACE; HR = 4.17; 95% CI: 1.64-8.33, p = 0.039) remained significantly associated with recurrence. In conclusion, SR was associated with significantly higher OS and PFS rates than TACE before and after PSM for single large HCC patients.

Indexed as

Carcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsFemaleHumansMaleMiddle AgedPrognosisPropensity ScoreRetrospective StudiesTreatment Outcomelarge hepatocellular carcinomaoverall survivalprogression-free survivalsurgical resectiontransarterial chemoembolization

Identifiers

PMID36625289
PMCPMC11895981
OpenAlexW4315437019

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.